Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.
Feature | Cath Lab | By Dave Fornell, Editor
Creating a Cardio-renal Program to Expand Patient Volume

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal ...

Home May 14, 2021
Home
Explaining the Emory TMVR angle. Discordance between mitral annular centerline (yellow lines) and valve orientation imposed by guidewire position within the LV apex (red dashed lines). (B) Valve intrinsic angle (α) is determined by external skirt height. (C) When annular-apical “Emory” angle (red curves) exceeds α (blue curve), annular skirt apposition is not possible, causing PVL (red arrows). (D) The valve is oriented perpendicular to the annual plane using an exteriorized apical guidewire.
Feature | Structural Heart | By Dave Fornell, Editor
The Emory Angle Can Help Eliminate Paravalvular Leak in Transcatheter Mitral Interventions

The mitral valve anatomy is extremely complex, which has caused many challenges for transcatheter mitral valve ...

Home May 13, 2021
Home
Videos | Structural Heart
VIDEO: Harmony Transcatheter Pulmonary Valve Has Good Outcomes at 1 Year

Tom Jones, M.D., director, cardiac catheterization laboratories, Seattle Children’s Hospital, and principle investigator ...

Home May 13, 2021
Home
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc
News | Cath Lab
Abbott’s New Artificial Intelligence OCT Coronary Imaging Platform Launches in Europe

May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has ...

Home May 12, 2021
Home
The BioCardia cardiac stem cell CardiAMP trial is a Phase III study looking at the efficacy of using stem cells to improve heart function in heart failure patients. It is the first trial for this technology to reach Phase III trial.
Feature | Stem Cell Therapies | By Simon H. Stertzer, M.D.
Is Cardiac Cell Therapy Worth Another Look?

Heart failure remains an unheralded global pandemic, costing society billions of dollars each year.[1,2] Projections ...

Home May 11, 2021
Home
Videos | Structural Heart
VIDEO: VARC-3 Helps Standardize Structural Heart Taxonomy and Research

Philippe Géneréux, M.D., director of the structural heart program at Atlantic Health System’s Morristown Medical Center ...

Home May 10, 2021
Home
Videos | Radial Access
VIDEO: Radial Hemostasis Reduced by 50 Percent With StatSeal in Combination With TR Band

Arnold Seto, M.D., MPA, FSCAI, chief of cardiology, Long Beach Veterans Affairs Medical Center and director ...

Home May 06, 2021
Home
Videos | Coronavirus (COVID-19)
VIDEO: The Impact of COVID-19 on Heart Attack Patients

Payam Dehghani, M.D.,  FRCPC, FACC, FSCAI, co-director of Prairie Vascular Research and associate professor at the ...

Home May 06, 2021
Home
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021
Feature | Cath Lab | By Dave Fornell, Editor
SCAI 2021 Late-breaking Clinical Study Results

April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from the ...

Home May 06, 2021
Home
Videos | Cath Lab
VIDEO: Avoiding Higher Risk Cath Lab Patients May Not Improve Outcomes Scores

Ashwin Nathan M.D., a cardiology fellow in the division of Cardiovascular Medicine at the Hospital of the University of ...

Home May 05, 2021
Home
The Corindus CorPath robotic cath lab navigation system allows operators to sit and control the procedure from behind a lead-lined booth, so they do not have to wear heavy aprons during the procedures.  Christoper Baker, M.D., Hoag Memorial Hospital using the system. #SCAI21 #SCAI2021
Feature | Robotic Systems
Second Generation Robotic PCI System Performs Well Across Spectrum of Lesion Complexity

May 5, 2021 — A late-breaking study of the Siemens Healthineers Corindus Corpath GRX second-generation cath lab robotic ...

Home May 05, 2021
Home
Avoiding high-risk PCI procedures does not improve hospital scores according to a study presented at SCAI 2021. CTO procedure at Henry Ford Hospital, Detroit. Photo by Dave Fornell.
News | Cardiovascular Business
Avoiding High-risk Cath Lab Procedures Does Not Necessarily Improve Hospital Scores

May 5, 2021 — A late-breaking study presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 202 ...

Home May 05, 2021
Home
If MitraClip Fails 95 Percent of Patients Will Need Full Surgical Valve Replacement according to a late-breaking study at the AATS 2021 meeting. #AATS2021
News | Heart Valve Technology
If MitraClip Fails 95 Percent of Patients Will Need Surgical Valve Replacement

May 4, 2021 – A new study, presented at the 2021 American Association for Thoracic Surgery (AATS) 101st annual meeting ...

Home May 04, 2021
Home
One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial infarction (STEMI), according to the latest, comprehensive data from The North American COVID-19 Myocardial Infarction (NACMI) Registry. The data was presented as a late-breaking study at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions. The study showed there was an alarming one-in-three patients dying with STEMI and COVID, compared to 4-in-100 #SCAI2021
Feature | Coronavirus (COVID-19) | By Dave Fornell, Editor
Third of COVID Patients With STEMI Heart Attacks Die

May 3, 2021 – One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial ...

Home May 03, 2021
Home
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images
News | Cath Lab
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria

May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for stable ...

Home May 03, 2021
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now